Chronic obstructive pulmonary disease with lung cancer and/or cardiovascular disease.

Chronic obstructive pulmonary disease (COPD) has been identified as an enormous growing worldwide health problem associated with long-term exposure to toxic gases and particles, most often related to cigarette smoking, heavily challenging our current millennium. The present article briefly reviews the evidence of the causes of death in COPD, while focusing on the impact of two of their most common and characteristic systemic effects, also named comorbidities-namely, lung cancer and cardiovascular disease-and drawing the attention to a new field of growing interest, namely the metabolic syndrome, and its potential interplay with the natural course of COPD. A comorbidity is defined as one or more distinct disorders (or diseases) in addition to COPD, regardless of whether this condition is or is not directly related to COPD, and irrespective of whether it is or is not part of the spectrum of the natural history of COPD.

[1]  A. Jemal,et al.  Trends in the leading causes of death in the United States, 1970-2002. , 2005, JAMA.

[2]  K. Rabe,et al.  From COPD to chronic systemic inflammatory syndrome? , 2007, The Lancet.

[3]  M. Decramer,et al.  Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey , 2002, European Respiratory Journal.

[4]  F. Crea,et al.  Widespread coronary inflammation in unstable angina. , 2003, The New England journal of medicine.

[5]  D. Forman,et al.  Delays in managing lung cancer. , 2004, Thorax.

[6]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[7]  K. R. Chapman,et al.  Epidemiology and costs of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.

[8]  W. Kannel,et al.  Pulmonary Function: Relation to Aging, Cigarette Habit, and Mortality , 1975 .

[9]  Alan D. Lopez,et al.  Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study , 1997, The Lancet.

[10]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[11]  M. Spitz,et al.  The Biology of Tobacco and Nicotine: Bench to Bedside , 2005, Cancer Epidemiology Biomarkers & Prevention.

[12]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[13]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[14]  A. Agustí Thomas a. Neff lecture. Chronic obstructive pulmonary disease: a systemic disease. , 2006, Proceedings of the American Thoracic Society.

[15]  J. Barberà,et al.  [Diagnosis and management of chronic obstructive pulmonary disease: joint guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Latin American Thoracic Society (ALAT)]. , 2008, Archivos de bronconeumologia.

[16]  P. Sterk Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1 , 2004, European Respiratory Journal.

[17]  C. Block,et al.  Mechanisms linking obesity with cardiovascular disease , 2006, Nature.

[18]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[19]  G. Davey Smith,et al.  The natural history of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.

[20]  Taghreed Adam,et al.  The burden and costs of chronic diseases in low-income and middle-income countries , 2007, The Lancet.

[21]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[22]  M. Ferrer,et al.  Chronic Obstructive Pulmonary Disease Stage and Health-Related Quality of Life , 1997, Annals of Internal Medicine.

[23]  Sherman Cb Health effects of cigarette smoking. , 1991 .

[24]  P. Paré,et al.  The nature of small-airway obstruction in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[25]  K. Chapman Chronic obstructive pulmonary disease: are women more susceptible than men? , 2004, Clinics in chest medicine.

[26]  A Senthilselvan,et al.  Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis , 2004, Thorax.

[27]  C. D. Mathers,et al.  Chronic obstructive pulmonary disease: current burden and future projections , 2006, European Respiratory Journal.

[28]  John Connett,et al.  The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality , 2005, Annals of Internal Medicine.

[29]  A. Buist,et al.  The Lung Health Study. Baseline characteristics of randomized participants. , 1993, Chest.

[30]  D. Postma,et al.  Relation between duration of smoking cessation and bronchial inflammation in COPD , 2005, Thorax.

[31]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[32]  R. Taylor,et al.  NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (NICE) , 2002, International Journal of Technology Assessment in Health Care.

[33]  X. Busquets,et al.  Systemic effects of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[34]  E. Wouters,et al.  Nutritional abnormalities and supplementation in chronic obstructive pulmonary disease. , 2000, Clinics in chest medicine.

[35]  K. Rabe,et al.  Complex chronic comorbidities of COPD , 2008, European Respiratory Journal.

[36]  R. Stockley,et al.  Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity – a common inflammatory phenotype? , 2006, Respiratory research.

[37]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[38]  E. Wouters,et al.  Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. , 1996, Thorax.

[39]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[40]  N. Anthonisen,et al.  Mortality in COPD: role of comorbidities , 2006, European Respiratory Journal.

[41]  D. Mannino,et al.  Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. , 2003, Archives of internal medicine.

[42]  Karel G M Moons,et al.  Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study , 2005, BMJ : British Medical Journal.

[43]  S. Suissa,et al.  Cardiovascular morbidity and mortality in COPD. , 2005, Chest.

[44]  J. Wedzicha,et al.  Causes of death in patients with COPD and chronic respiratory failure. , 1997, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[45]  Judith K Jones,et al.  Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. , 2006, Annals of epidemiology.

[46]  F. Rutten,et al.  Heart failure and chronic obstructive pulmonary disease: An ignored combination? , 2006, European journal of heart failure.

[47]  A. Agustí,et al.  Chronic obstructive pulmonary disease : A systemic disease , 2006 .

[48]  E. Wouters,et al.  Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[49]  François G Schellevis,et al.  Comorbidity and guidelines: conflicting interests , 2006, The Lancet.

[50]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[51]  D. Jacobs,et al.  Cigarette smoking and mortality risk: twenty-five-year follow-up of the Seven Countries Study. , 1999, Archives of internal medicine.